OpGen
Nasdaq Affirms OpGen's Delisting Decision
The molecular diagnostics developer has appealed the decision and said its stock will continue to trade on the OTC markets in the meantime.
OpGen Shares Suspended From Trading on Nasdaq
The suspension comes as the molecular diagnostics firm struggles to meet the Nasdaq's minimum stockholders’ equity requirement.
OpGen Submits Plan to Nasdaq After Missing Another Listing Requirement
The company has struggled to stay afloat after the bankruptcy of its European subsidiaries and the sale of most of its remaining assets.
In Brief This Week: Becton Dickinson; Delfi Diagnostics; OpGen; GeneDx; Angle
News items for the week of June 3, 2024.
OpGen Out of Compliance With Additional Nasdaq Listing Requirement
After failing to meet Nasdaq's minimum bid price requirement, OpGen was also notified that it didn't meet the exchange's requirement that it file a quarterly financial report.
May 16, 2024
OpGen to Execute 1-for-10 Reverse Stock Split
Apr 24, 2024
Nasdaq Warns OpGen About Overdue 2023 Annual Report
Dec 13, 2023
OpGen Requests Hearing on Nasdaq Delisting
May 2, 2023